Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation

Michael Roth, Britta Will, Guillermo Simkin, Swathi-Rao Narayanagari, Laura Barreyro, Boris A. Bartholdy, Roni Tamari, Constantine S. Mitsiades, Amit K. Verma, Ulrich G. Steidl

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Eltrombopag (EP) is a small-molecule, nonpeptide thrombopoietin receptor (TPO-R) agonist that has been approved recently for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura. Prior studies have shown that EP stimulates megakaryopoiesis in BM cells from patients with acute myeloid leukemia and myelodysplastic syndrome, and the results also suggested that it may inhibit leukemia cell growth. In the present study, we studied the effects of EP on leukemia cell proliferation and the mechanism of its antiproliferative effects.We found that EP leads to a decreased cell division rate, a block in G 1 phase of cell cycle, and increased differentiation in human and murine leukemia cells. Because EP is species specific in that it can only bind TPO-R in human and primate cells, these findings further suggested that the anti-leukemic effect is independent of TPO-R. We found that treatment with EP leads to a reduction in free intracellular iron in leukemic cells in a dose-dependent manner. Experimental increase of intracellular iron abrogated the antiproliferative and differentiation-inducing effects of EP, demonstrating that its antileukemic effects are mediated through modulation of intracellular iron content. Finally, determination of EP's antileukemic activity in vivo demonstrated its ability to prolong survival in 2 mouse models of leukemia.

Original languageEnglish (US)
Pages (from-to)386-394
Number of pages9
JournalBlood
Volume120
Issue number2
DOIs
StatePublished - Jul 12 2012

Fingerprint

Leukemia
Iron
Cell Proliferation
Thrombopoietin Receptors
Cells
Idiopathic Thrombocytopenic Purpura
Myelodysplastic Syndromes
Cell proliferation
Cell growth
eltrombopag
Acute Myeloid Leukemia
Thrombocytopenia
Cell Division
Primates
Cell Cycle
Modulation
Molecules
Survival
Therapeutics
Growth

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. / Roth, Michael; Will, Britta; Simkin, Guillermo; Narayanagari, Swathi-Rao; Barreyro, Laura; Bartholdy, Boris A.; Tamari, Roni; Mitsiades, Constantine S.; Verma, Amit K.; Steidl, Ulrich G.

In: Blood, Vol. 120, No. 2, 12.07.2012, p. 386-394.

Research output: Contribution to journalArticle

@article{9913a12cedda4554aed967c728b46bc3,
title = "Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation",
abstract = "Eltrombopag (EP) is a small-molecule, nonpeptide thrombopoietin receptor (TPO-R) agonist that has been approved recently for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura. Prior studies have shown that EP stimulates megakaryopoiesis in BM cells from patients with acute myeloid leukemia and myelodysplastic syndrome, and the results also suggested that it may inhibit leukemia cell growth. In the present study, we studied the effects of EP on leukemia cell proliferation and the mechanism of its antiproliferative effects.We found that EP leads to a decreased cell division rate, a block in G 1 phase of cell cycle, and increased differentiation in human and murine leukemia cells. Because EP is species specific in that it can only bind TPO-R in human and primate cells, these findings further suggested that the anti-leukemic effect is independent of TPO-R. We found that treatment with EP leads to a reduction in free intracellular iron in leukemic cells in a dose-dependent manner. Experimental increase of intracellular iron abrogated the antiproliferative and differentiation-inducing effects of EP, demonstrating that its antileukemic effects are mediated through modulation of intracellular iron content. Finally, determination of EP's antileukemic activity in vivo demonstrated its ability to prolong survival in 2 mouse models of leukemia.",
author = "Michael Roth and Britta Will and Guillermo Simkin and Swathi-Rao Narayanagari and Laura Barreyro and Bartholdy, {Boris A.} and Roni Tamari and Mitsiades, {Constantine S.} and Verma, {Amit K.} and Steidl, {Ulrich G.}",
year = "2012",
month = "7",
day = "12",
doi = "10.1182/blood-2011-12-399667",
language = "English (US)",
volume = "120",
pages = "386--394",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation

AU - Roth, Michael

AU - Will, Britta

AU - Simkin, Guillermo

AU - Narayanagari, Swathi-Rao

AU - Barreyro, Laura

AU - Bartholdy, Boris A.

AU - Tamari, Roni

AU - Mitsiades, Constantine S.

AU - Verma, Amit K.

AU - Steidl, Ulrich G.

PY - 2012/7/12

Y1 - 2012/7/12

N2 - Eltrombopag (EP) is a small-molecule, nonpeptide thrombopoietin receptor (TPO-R) agonist that has been approved recently for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura. Prior studies have shown that EP stimulates megakaryopoiesis in BM cells from patients with acute myeloid leukemia and myelodysplastic syndrome, and the results also suggested that it may inhibit leukemia cell growth. In the present study, we studied the effects of EP on leukemia cell proliferation and the mechanism of its antiproliferative effects.We found that EP leads to a decreased cell division rate, a block in G 1 phase of cell cycle, and increased differentiation in human and murine leukemia cells. Because EP is species specific in that it can only bind TPO-R in human and primate cells, these findings further suggested that the anti-leukemic effect is independent of TPO-R. We found that treatment with EP leads to a reduction in free intracellular iron in leukemic cells in a dose-dependent manner. Experimental increase of intracellular iron abrogated the antiproliferative and differentiation-inducing effects of EP, demonstrating that its antileukemic effects are mediated through modulation of intracellular iron content. Finally, determination of EP's antileukemic activity in vivo demonstrated its ability to prolong survival in 2 mouse models of leukemia.

AB - Eltrombopag (EP) is a small-molecule, nonpeptide thrombopoietin receptor (TPO-R) agonist that has been approved recently for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura. Prior studies have shown that EP stimulates megakaryopoiesis in BM cells from patients with acute myeloid leukemia and myelodysplastic syndrome, and the results also suggested that it may inhibit leukemia cell growth. In the present study, we studied the effects of EP on leukemia cell proliferation and the mechanism of its antiproliferative effects.We found that EP leads to a decreased cell division rate, a block in G 1 phase of cell cycle, and increased differentiation in human and murine leukemia cells. Because EP is species specific in that it can only bind TPO-R in human and primate cells, these findings further suggested that the anti-leukemic effect is independent of TPO-R. We found that treatment with EP leads to a reduction in free intracellular iron in leukemic cells in a dose-dependent manner. Experimental increase of intracellular iron abrogated the antiproliferative and differentiation-inducing effects of EP, demonstrating that its antileukemic effects are mediated through modulation of intracellular iron content. Finally, determination of EP's antileukemic activity in vivo demonstrated its ability to prolong survival in 2 mouse models of leukemia.

UR - http://www.scopus.com/inward/record.url?scp=84864053179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864053179&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-12-399667

DO - 10.1182/blood-2011-12-399667

M3 - Article

C2 - 22627766

AN - SCOPUS:84864053179

VL - 120

SP - 386

EP - 394

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -